Next Phase Newsletter

A private equity firm founded in 2014 and is based in New York and Montreal. The firm manages the a fund that provides equity and equity-like investments in high growth companies in healthcare technology verticals, with a focus on surgery. The size of investments generally fall under the range of $2-5 M per company, and the firm seeks to make 2-3 investments per year. The firm looks globally with a strong focus in North America.

The firm is interested in highly innovative medical and surgical device companies, healthcare IT, healthcare services. The firm will not consider products in pharma or biotech industries. Medical device products should be patented and on the cusp of FDA clearance. The firm will support all classes of medical devices including 510k and PMA regulatory pathways. Healthcare IT companies are expected to demonstrate market traction prior to investment.

The firm seeks to work with companies with an experienced, motivated management team. The firm can act as the lead investor in all financing rounds, and requires a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical company based in Asia is actively searching for innovative candidates and products around the world to incorporate into its pipeline and product portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.

The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. In terms of indications, the firm is indication agnostic with added interest in movement disorders, CNS, liver disease and immunology. The firm is also interested in oncology indications (small molecule or biologics with novel MoA). The firm prefers assets both in early/late non-clinical development stage as well as in early clinical development stage.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners; the firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third party relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the Benelux region is focused on identifying and investing in promising European companies. The firm generally invests from the very early stages from Seed to Series A and often acts as the first institutional investor, but also reserves 1/3 of the fund to more late-stage opportunities as well. The firm could invest as little as $200K or up to $3M in a first investment round, depending on the company’s current stage of development. The firm seeks to invest in companies that have a presence in Europe.

The firm invests broadly across therapeutics, diagnostics, and agriculture, but does not invest in medical devices, healthcare IT, or bioinformatics. The is open to all different types of technologies and indications.

The firm can act as either a lead or co-investor. In cases where the firm acts as the first institutional investor, the firm will seek board representation and take an active role in helping the company grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm in Taiwan invests in breakthrough technologies changing healthcare. The firm invests from seed-Series A. The fund’s LP’s include groups in the healthcare sector.

The firm invests in early stage life science startups with a focus on breakthrough technologies and sciences in healthcare. This includes genomic and synthetic biology technologies, digital health, ML/AI, therapeutics and diagnostics. The firm focuses on pre-IND assets in therapeutics. For technologies regulated as medical devices, the firm focuses on smart medical devices in the pre-commercial stage.

The firm’s partners have a strong clinical perspective; the firm has the capability to help portfolio companies develop clinical resources, and has helped academic scientists form companies to commercialize their discoveries.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A subsidiary of a company that is sponsored by family offices in China is focused on research and distribution of class 2 and 3 medical devices in China, and is one of the major distributors for some of the largest multinational companies. Having offices in both USA and China, the firm has invested in companies that are based in greater Boston area, Los Angeles as well as Canada. The firm has a fund size of $30M, and the typical allocation ranges from $0.5M – $1M, with no specific limit. The firm has invested over 10 companies by now and will continue to expand its portfolio.

The firm is open to therapeutics and medical device companies, but is most interested in in-vitro diagnostic technologies. The firm is looking for companies that are in development or in the pre-clinical stage. The firm mostly invests in seed round but will invest up to pre-A. The firm is also interested in in-licensing opportunities in China as well.

The firm invests globally and does not have specific requirements regarding companies or their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early stage venture fund based in the USA generally makes equity investments in Healthcare IT and Pharma IT companies at growth stage. The typical investment size ranges from $1 million to $3 million. The firm focuses on companies based in the mid-Atlantic region of the USA.

The firm is currently looking for new opportunities in the Healthcare IT and Pharma IT sectors. The firm will not consider devices or biotech companies. The firm typically invests in companies that have started to generate revenues.

The firm focuses on private companies with between $1 million to $3 million in revenue. The firm prefers investments in companies with a strong management team and significant growth potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment company with base operations in China manages a￥3000M fund. The typical allocation size of the firm ranges from ￥50M to ￥100M (~$7 to 14M USD). The firm is generally interested in companies in therapeutics, medical devices, diagnostics, and healthcare IT areas.

The firm is interested in the medical device, diagnostics, and Healthcare IT companies. Within the therapeutics sector, the firm will mainly look at CRO and CDMO companies and it prefers companies with unique R&D platforms. The firm will look at companies that are in development and it is most interested in companies that are closed to commercialize or are already on the market. The firm prefers to invest in early-stage companies that are FDA/CE/NMPA approved or are closed to getting NMPA approval. The firm is willing to help its portfolio companies to expand their commercialization in Chinese market.

The firm prefers companies from China, but will also invest in foreign companies with China angles or China market or those who have branches in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.